JP2023529884A - コラーゲン１翻訳阻害剤及びその使用方法 - Google Patents

コラーゲン１翻訳阻害剤及びその使用方法 Download PDF

Info

Publication number
JP2023529884A
JP2023529884A JP2022575730A JP2022575730A JP2023529884A JP 2023529884 A JP2023529884 A JP 2023529884A JP 2022575730 A JP2022575730 A JP 2022575730A JP 2022575730 A JP2022575730 A JP 2022575730A JP 2023529884 A JP2023529884 A JP 2023529884A
Authority
JP
Japan
Prior art keywords
substituted
compound
unsubstituted
branched
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022575730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529884A5 (https=
Inventor
シェパード、デイヴィッド・ウィリアム
ティアニー、ジェイソン・ポール
マンダビ、アヴィアド
シュミット、ウォルフガング
レヴァント、ステファノ
ハンブリン、ジュリー・ニコール
ブル、リチャード・ジェームス
アーロイ、アイリス
マンスール、ウィッサム
クレプフィッシュ、モーティ
ワン、ヤオデ
リー、ハイタン
Original Assignee
アニマ バイオテック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アニマ バイオテック インコーポレイテッド filed Critical アニマ バイオテック インコーポレイテッド
Publication of JP2023529884A publication Critical patent/JP2023529884A/ja
Publication of JP2023529884A5 publication Critical patent/JP2023529884A5/ja
Priority to JP2025169543A priority Critical patent/JP2026010018A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022575730A 2020-06-09 2021-06-09 コラーゲン１翻訳阻害剤及びその使用方法 Pending JP2023529884A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025169543A JP2026010018A (ja) 2020-06-09 2025-10-07 コラーゲン１翻訳阻害剤及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036458P 2020-06-09 2020-06-09
US63/036,458 2020-06-09
PCT/US2021/036505 WO2021252555A1 (en) 2020-06-09 2021-06-09 Collagen 1 translation inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025169543A Division JP2026010018A (ja) 2020-06-09 2025-10-07 コラーゲン１翻訳阻害剤及びその使用方法

Publications (2)

Publication Number Publication Date
JP2023529884A true JP2023529884A (ja) 2023-07-12
JP2023529884A5 JP2023529884A5 (https=) 2025-02-26

Family

ID=78845874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022575730A Pending JP2023529884A (ja) 2020-06-09 2021-06-09 コラーゲン１翻訳阻害剤及びその使用方法
JP2025169543A Pending JP2026010018A (ja) 2020-06-09 2025-10-07 コラーゲン１翻訳阻害剤及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025169543A Pending JP2026010018A (ja) 2020-06-09 2025-10-07 コラーゲン１翻訳阻害剤及びその使用方法

Country Status (8)

Country Link
US (1) US20230212131A1 (https=)
EP (1) EP4161921A4 (https=)
JP (2) JP2023529884A (https=)
CN (1) CN115916776A (https=)
AU (1) AU2021288584A1 (https=)
CA (1) CA3179059A1 (https=)
IL (1) IL298475A (https=)
WO (1) WO2021252555A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20167018A7 (fi) * 2016-12-30 2018-07-01 Andras Kovacs Menetelmä ja laitteisto energian tuottamiseksi metalliseoksesta
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
PL4514782T3 (pl) 2022-05-19 2026-02-23 Astrazeneca Ab Związki amidoheteroaromatyczne przydatne w leczeniu chorób wątroby
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
IL310685B2 (en) * 2024-02-06 2026-02-01 Anima Biotech Inc Collagen-1 translation inhibitors and methods of using them
CN119874697A (zh) * 2025-03-03 2025-04-25 成都大学 一种噻唑酰胺衍生物的制备方法和在治疗炎症中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502014A (ja) * 1991-06-21 1995-03-02 ベーリンガー　マンハイム　イタリア　エス．ピー．エイ． 気道に対して抗喘息性、抗炎症性活性を有する２−アミノ−４−アリール−チアゾール
WO2002059099A1 (en) * 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Cyclic compounds having thrombopoietin receptor agonism
JP2008505872A (ja) * 2004-07-09 2008-02-28 サノフイ−アベンテイス ２−カルバミド−４−フェニルチアゾール誘導体、この調製およびこの治療的使用
JP2009507065A (ja) * 2005-09-07 2009-02-19 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ヒストン脱アセチル化酵素（ｈｄａｃ）阻害剤としてのチオフェン及びチアゾール置換トリフルオロエタノン誘導体
WO2014133056A1 (ja) * 2013-02-28 2014-09-04 アステラス製薬株式会社 ２－アシルアミノチアゾール誘導体またはその塩
JP2014526537A (ja) * 2011-09-23 2014-10-06 バイヤースドルフ・アクチエンゲゼルシヤフト 複素環カルボニルアミノチアゾール、それを含有する化粧用または皮膚科用製剤、および望ましくない皮膚の色素沈着を治療・予防するためのその使用
JP2017505295A (ja) * 2013-12-19 2017-02-16 バイエルスドルフ・アクチエンゲゼルシヤフトＢｅｉｅｒｓｄｏｒｆ ＡＧ 敏感肌の予防及び治療のための、化粧品用又は皮膚用調製物におけるアルキルアミドチアゾールの使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000441A (es) * 2003-07-17 2006-04-05 Astellas Pharma Inc Derivado de 2-acilaminotiazole o sal del mismo.
US20070167499A1 (en) * 2003-10-27 2007-07-19 A*Bio Pte Ltd. Biaryl linked hydroxamates: preparation and pharmaceutical applications
MXPA06008606A (es) * 2004-01-30 2007-04-13 Vertex Pharma Moduladores de transportadores con casete de union a atp.
AR049333A1 (es) * 2004-04-02 2006-07-19 Vertex Pharma Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
CA2573426C (en) * 2004-07-30 2015-11-17 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
WO2007004038A1 (en) * 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JP5705748B2 (ja) * 2009-02-18 2015-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する複素環化合物
NZ604831A (en) * 2010-07-02 2014-12-24 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors
JP6097998B2 (ja) * 2010-12-16 2017-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のビアリールアミドインヒビター
US9512116B2 (en) * 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2016115463A1 (en) * 2015-01-15 2016-07-21 Whitehead Institute For Biomedical Research Inhibitors of phosphoglycerate dehydrogenase (phgdh) and uses thereof
WO2017009650A1 (en) * 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
WO2017035351A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017066225A1 (en) * 2015-10-14 2017-04-20 Texas Tech University System Pharmacoperones of the v2 receptor
JPWO2017170860A1 (ja) * 2016-03-30 2019-02-07 東レ株式会社 ヒートショックプロテイン４７阻害剤
JP2019513762A (ja) * 2016-04-11 2019-05-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞及び線維症の処置方法
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
EA201992780A1 (ru) * 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
WO2019028104A1 (en) * 2017-08-02 2019-02-07 Alphala Co., Ltd. NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
DE102018211412A1 (de) * 2018-07-10 2020-01-16 Beiersdorf Ag Selbstklebende flächige Produkte enthaltend ein oder mehrere Alkylamidothiazole
US20210380546A1 (en) * 2018-10-22 2021-12-09 The Regents Of The University Of California Vaccine adjuvant

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502014A (ja) * 1991-06-21 1995-03-02 ベーリンガー　マンハイム　イタリア　エス．ピー．エイ． 気道に対して抗喘息性、抗炎症性活性を有する２−アミノ−４−アリール−チアゾール
WO2002059099A1 (en) * 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Cyclic compounds having thrombopoietin receptor agonism
JP2008505872A (ja) * 2004-07-09 2008-02-28 サノフイ−アベンテイス ２−カルバミド−４−フェニルチアゾール誘導体、この調製およびこの治療的使用
JP2009507065A (ja) * 2005-09-07 2009-02-19 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ヒストン脱アセチル化酵素（ｈｄａｃ）阻害剤としてのチオフェン及びチアゾール置換トリフルオロエタノン誘導体
JP2014526537A (ja) * 2011-09-23 2014-10-06 バイヤースドルフ・アクチエンゲゼルシヤフト 複素環カルボニルアミノチアゾール、それを含有する化粧用または皮膚科用製剤、および望ましくない皮膚の色素沈着を治療・予防するためのその使用
WO2014133056A1 (ja) * 2013-02-28 2014-09-04 アステラス製薬株式会社 ２－アシルアミノチアゾール誘導体またはその塩
JP2017505295A (ja) * 2013-12-19 2017-02-16 バイエルスドルフ・アクチエンゲゼルシヤフトＢｅｉｅｒｓｄｏｒｆ ＡＧ 敏感肌の予防及び治療のための、化粧品用又は皮膚用調製物におけるアルキルアミドチアゾールの使用

Also Published As

Publication number Publication date
CA3179059A1 (en) 2021-12-16
US20230212131A1 (en) 2023-07-06
WO2021252555A1 (en) 2021-12-16
AU2021288584A1 (en) 2023-01-19
JP2026010018A (ja) 2026-01-21
CN115916776A (zh) 2023-04-04
EP4161921A4 (en) 2024-06-19
IL298475A (en) 2023-01-01
EP4161921A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
JP2023529884A (ja) コラーゲン１翻訳阻害剤及びその使用方法
CN115427404B (zh) 胶原蛋白1翻译抑制剂和其使用方法
JP2025087798A (ja) コラーゲン１翻訳阻害剤およびその使用方法
US20240279215A1 (en) Nampt modulators
US20220370431A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
EP3022193B1 (en) Inhibitors of leukotriene production
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
US12404283B2 (en) c-MYC mRNA translation modulators and uses thereof in the treatment of cancer
AU2023305002A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251007